Peregrine Pharmaceuticals to Join Russell 3000 and Russell Global Indexes

Peregrine Pharmaceuticals to Join Russell 3000 and Russell Global Indexes 
TUSTIN, CA -- (Marketwired) -- 06/24/13 --  Peregrine Pharmaceuticals
(NASDAQ: PPHM) today announced that it has received notification it
will join the Russell 3000(R) and Russell Global Indexes when Russell
Investments reconstitutes its family of U.S. indexes on June 28,
2013, according to a list of additions posted on June 21, 2013.  
The Russell Indexes capture the 4,000 largest U.S. stocks as of the
end of May, ranking them by total market capitalization. Russell
indexes are reconstituted annually and are widely used by investment
managers and institutional investors for index funds and as
benchmarks for both passive and active investment strategies.
Approximately $4.1 trillion in assets are benchmarked to the Russell
Indexes. 
Membership in the Russell 3000(R), which remains in place for one
year, means automatic inclusion in the large-cap Russell 1000(R)
Index or small-cap Russell 2000(R) Index, as well as the appropriate
growth and value style indexes. The Russell 3000 also serves as the
U.S. component to the Russell Global Index. Membership in the Russell
Global Index, which remains in place for one year, means automatic
inclusion in the appropriate large-cap, small-cap, all-cap indexes as
well as the applicable style, sector and country indexes. Russell
determines membership for its equity indexes primarily by objective,
market capitalization rankings and style attributes. 
More information on the Russell Indexes, including total returns, is
available at http://www.russell.com/Indexes/data/default.asp. 
About Peregrine Pharmaceuticals, Inc.
 Peregrine Pharmaceuticals,
Inc. is a biopharmaceutical company with a portfolio of innovative
monoclonal antibodies in clinical trials focused on the treatment and
diagnosis of cancer. The company is pursuing multiple clinical
programs in cancer with its lead immunotherapy candidate bavituximab
and novel brain cancer agent Cotara(R). Peregrine also has in-house
cGMP manufacturing capabilities through its wholly-owned subsidiary
Avid Bioservices, Inc. (www.avidbio.com), which provides development
and biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found at
www.peregrineinc.com. 
Contact:
Christopher Keenan or Jay Carlson 
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com 
 
 
Press spacebar to pause and continue. Press esc to stop.